Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study

Citation for published version (APA): Flinterman, L. E., Kuiper, J. G., Korevaar, J. C., van Dijk, L., Hek, K., Houben, E., Herings, R., Franken, A. A. M., de Graaf, J. P., Horikx, A., Janssens, M., Meijer, R., Wijbenga, A., van Puijenbroek, E., Wolffenbuttel, B. H. R., Links, T. P., Bisschop, P. H., & Fliers, E. (2020). Impact of a Forced DoseEquivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study. Thyroid, 30(6), 821-828. https://doi.org/10.1089/thy.2019.0414

[1]  E. Fliers,et al.  European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries , 2018, European Thyroid Journal.

[2]  J. Janowsky,et al.  Effects of Altering Levothyroxine (L-T4) Doses on Quality of Life, Mood, and Cognition in L-T4 Treated Subjects , 2018, The Journal of clinical endocrinology and metabolism.

[3]  B. Casassus.  Risks of reformulation: French patients complain after Merck modifies levothyroxine pills , 2018, British Medical Journal.

[4]  P. Trimboli,et al.  Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis , 2018, Front. Endocrinol..

[5]  G. Kahaly,et al.  New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials , 2017, Current medical research and opinion.

[6]  W. Wiersinga.  Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism , 2014, Nature Reviews Endocrinology.

[7]  Rosalind S. Brown,et al.  Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[8]  V. Burke,et al.  Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. , 2006, The Journal of clinical endocrinology and metabolism.

[9]  Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. , 2004, Thyroid : official journal of the American Thyroid Association.